Skip to main content

Table 3 Demographic characteristic and biochemical analysis in MS and control sub-groups

From: Reduction in circulating vitamin D binding protein in patients with multiple sclerosis

Demographic characteristic MS (N = 77) Control (N = 67) p-value
Age (years)† 33.68 ± 8.16 34.71 ± 6.45 0.89
Sex (Women)‡ 76.9% (60) 76.6% (52) 0.94
BMI (kg/m2)† 24.66 ± 4.47 24.19 ± 3.81 0.49
Clinical outcomes
 MS Duration (month)†† 4.02 (8)  
 MS diagnosis age (years)† 33.60 ± 7.81  
 Smoking‡ 10.0% (7) 6.0% (4) 0.52
 Vitamin D levels† 33.60 ± 14.91 21.55 ± 12.49 0.0001
 Ln. VDBP levels (μgr/ml) † 3.64 ± 0.91 5.31 ± 0.77 0.0001
Albumin (g/dl)† 4.07 ± 0.81 4.10 ± 0.85 0.89
Taking vitamin D supplement ‡
 Regular 54.5% (42) 18.0% (12) 0.0001
 Irregular 17.0% (13) 35.8%(24)
 Never 28.5% (22) 46.2% (31)
Taking drug at the sampling time‡
No treatment 32.5% (25)  
Rituximab 11.7% (9)  
Natalizumab 2.6%(2)  
 Interferon B1a 26.0% (20)  
 Glatiramer acetate 9.1% (7)  
 Dimethyl fumarate 2.6% (2)  
 4 Aminopyridin 1.3% (1)  
 Fingolimod 13.0% (10)  
 Teriflunomide 1.3% (1)  
 Corticosteroids  
  1. Abbreviations: BMI body mass index, Ln natural logarithm
  2. mean ± SD, †† median (IQR), ‡%(N)